Literature DB >> 20177846

c-kit (CD117) expression in human tumors and its prognostic value: an immunohistochemical analysis.

Michael Medinger1, Manuela Kleinschmidt, Klaus Mross, Barbara Wehmeyer, Clemens Unger, Hans-Eckart Schaefer, Renate Weber, Marc Azemar.   

Abstract

c-kit functions as a tyrosine kinase receptor and represents a target for small molecule kinase inhibitors. The expression pattern for c-kit was studied in different human tumor types to their correlation with prognosis. Paraffin-embedded tumor tissues from 282 patients were analyzed immunohistochemically for c-kit expression. Survival and follow-up data were available from 192/282 (68%) patients. c-kit immunopositivity was found in 62/282 (22%) cases. c-kit expression was found in 14/83 (17%) colorectal cancers, in 13/62 (21%) breast cancers, in 7/20 sarcomas (35%), in 5/14 (36%) renal cell carcinomas, in 2/12 ovarian cancers (17%) and in 2/12 (17%) hepatocellular carcinomas. We found no significant correlation between c-kit expression and prognosis although a trend to a worse prognosis in patients with c-kit positive tumors could be observed. Expression of c-kit was found in tumor samples with varying intensities and infrequently.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20177846     DOI: 10.1007/s12253-010-9247-9

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  42 in total

1.  Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.

Authors:  H Joensuu; P J Roberts; M Sarlomo-Rikala; L C Andersson; P Tervahartiala; D Tuveson; S Silberman; R Capdeville; S Dimitrijevic; B Druker; G D Demetri
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

Review 2.  Signal transduction via the stem cell factor receptor/c-Kit.

Authors:  L Rönnstrand
Journal:  Cell Mol Life Sci       Date:  2004-10       Impact factor: 9.261

3.  A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study.

Authors:  G K Dy; A A Miller; S J Mandrekar; M-C Aubry; R M Langdon; R F Morton; S E Schild; J R Jett; A A Adjei
Journal:  Ann Oncol       Date:  2005-08-08       Impact factor: 32.976

4.  Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.

Authors:  M C Heinrich; D J Griffith; B J Druker; C L Wait; K A Ott; A J Zigler
Journal:  Blood       Date:  2000-08-01       Impact factor: 22.113

5.  Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.

Authors:  Michael C Heinrich; Heikki Joensuu; George D Demetri; Christopher L Corless; Jane Apperley; Jonathan A Fletcher; Denis Soulieres; Stephan Dirnhofer; Amy Harlow; Ajia Town; Arin McKinley; Shane G Supple; John Seymour; Lilla Di Scala; Allan van Oosterom; Richard Herrmann; Zariana Nikolova; And Grant McArthur
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

6.  Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium.

Authors:  Rosemarie E Schmandt; Russell Broaddus; Karen H Lu; Hyun Shvartsman; Angela Thornton; Anais Malpica; Charlotte Sun; Diane C Bodurka; David M Gershenson
Journal:  Cancer       Date:  2003-08-15       Impact factor: 6.860

7.  Expression of c-kit receptor in normal and transformed human nonlymphoid tissues.

Authors:  P G Natali; M R Nicotra; I Sures; E Santoro; A Bigotti; A Ullrich
Journal:  Cancer Res       Date:  1992-11-15       Impact factor: 12.701

8.  Rare KIT (CD117) expression in multiple myeloma abrogates the usefulness of imatinib mesylate treatment.

Authors:  A Lugli; P Went; B Khanlari; Z Nikolova; S Dirnhofer
Journal:  Virchows Arch       Date:  2003-12-16       Impact factor: 4.064

9.  KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors.

Authors:  Harri Sihto; Maarit Sarlomo-Rikala; Olli Tynninen; Minna Tanner; Leif C Andersson; Kaarle Franssila; Nina N Nupponen; Heikki Joensuu
Journal:  J Clin Oncol       Date:  2004-11-15       Impact factor: 44.544

10.  Immunohistochemical expression of the c-kit proto-oncogene product in human malignant and non-malignant breast tissues.

Authors:  X Chui; H Egami; J Yamashita; T Kurizaki; H Ohmachi; S Yamamoto; M Ogawa
Journal:  Br J Cancer       Date:  1996-05       Impact factor: 7.640

View more
  13 in total

1.  KIT Signaling Promotes Growth of Colon Xenograft Tumors in Mice and Is Up-Regulated in a Subset of Human Colon Cancers.

Authors:  Evan C Chen; Taylor A Karl; Tomer Kalisky; Santosh K Gupta; Catherine A O'Brien; Teri A Longacre; Matt van de Rijn; Stephen R Quake; Michael F Clarke; Michael E Rothenberg
Journal:  Gastroenterology       Date:  2015-05-28       Impact factor: 22.682

2.  Giant gastrointestinal stromal tumour of the stomach: a case report with surgical treatment.

Authors:  Y Zhang; Y J Wang; C J Lu; G M Shu; T Bai
Journal:  Ann R Coll Surg Engl       Date:  2018-02-27       Impact factor: 1.891

3.  Prognostic value of CD117 in cancer: a meta-analysis.

Authors:  Fuyou Zhao; Yuqing Chen; Qiong Wu; Zian Wang; Jie Lu
Journal:  Int J Clin Exp Pathol       Date:  2014-02-15

Review 4.  A rare giant gastrointestinal stromal tumor of the stomach traversing the upper abdomen: a case report and literature review.

Authors:  Lei Zhou; Chang Liu; Ji-Gang Bai; Ji-Chao Wei; Kai Qu; Feng Tian; Ming-Hui Tai; Rui-Tao Wang; Fan-Di Meng
Journal:  World J Surg Oncol       Date:  2012-04-27       Impact factor: 2.754

5.  CD117⁺ cells in the circulation are predictive of advanced prostate cancer.

Authors:  Bethany A Kerr; Ranko Miocinovic; Armine K Smith; Xiaoxia Z West; Katherine E Watts; Amanda W Alzayed; Joseph C Klink; Maria C Mir; Tiffany Sturey; Donna E Hansel; Warren D Heston; Andrew J Stephenson; Eric A Klein; Tatiana V Byzova
Journal:  Oncotarget       Date:  2015-01-30

6.  Altered expression of cytokeratin 7 and CD117 in transitional mucosa adjacent to human colorectal cancer.

Authors:  Hideaki Kigasawa; Masachika Fujiwara; Jun Ishii; Tomohiro Chiba; Yuichi Terado; Hiroaki Shimoyamada; Makoto Mochizuki; Osamu Kitamura; Hiroshi Kamma; Yasuo Ohkura
Journal:  Oncol Lett       Date:  2017-05-11       Impact factor: 2.967

Review 7.  CD117/c-kit in Cancer Stem Cell-Mediated Progression and Therapeutic Resistance.

Authors:  Brittni M Foster; Danish Zaidi; Tyler R Young; Mary E Mobley; Bethany A Kerr
Journal:  Biomedicines       Date:  2018-03-08

8.  CD117/c-kit defines a prostate CSC-like subpopulation driving progression and TKI resistance.

Authors:  Koran S Harris; Lihong Shi; Brittni M Foster; Mary E Mobley; Phyllis L Elliott; Conner J Song; Kounosuke Watabe; Carl D Langefeld; Bethany A Kerr
Journal:  Sci Rep       Date:  2021-01-14       Impact factor: 4.379

9.  Expression of Stem Cell Markers in Preinvasive Tubal Lesions of Ovarian Carcinoma.

Authors:  G Chene; V Ouellet; K Rahimi; V Barres; L Meunier; M De Ladurantaye; D Provencher; A M Mes-Masson
Journal:  Biomed Res Int       Date:  2015-10-04       Impact factor: 3.411

10.  Prognostic significance of CD117 expression and TP53 missense mutations in triple-negative breast cancer.

Authors:  Yanli Luo; Wentao Huang; Huizhen Zhang; Guang Liu
Journal:  Oncol Lett       Date:  2018-02-22       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.